The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...

A 25-year insider at Novo Nordisk, Jørgensen took the helm in January this year, and brought in new cost control measures, including job losses of 1,000 employees.

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and cardiometabolic diseases, leveraging AI and extensive human datasets.

Novo Nordisk has been one of the chief beneficiaries of the boom in GLP-1 drugs, which have shown great promise in fighting obesity. Competition in the space is fierce, but shares got a much ...